U.K. pulls manufacturing authorization from Bristol Laboratories

U.K. regulators have pulled the manufacturing certificate of generics maker Bristol Laboratories after finding some issues at its plant in Luton.

A generics maker in the U.K. had its manufacturing certification pulled after regulators found data reporting issues.

According to the European Medicines Agency, the action against Bristol Laboratories was taken following an inspection of the company’s facility in Luton in July. The company, founded in 1997, produces a portfolio of generic and over-the-counter, non-sterile capsules and tablets that it sells in the U.K. and Europe.

U.K. regulators provided few details about the issues uncovered, saying that there were two critical deficiencies relating to the integrity and recording of GMP critical data as well as issues with the facility’s ongoing stability-monitoring program.

On-Demand Webinar

De-Risking the Solid Form Landscape of an API

This presentation will discuss how predictable stability and solubility can minimize development timelines and cost. Attend to hear about two case studies exemplifying the importance of understanding the hydration space of an API and how hydrate formation may be avoided by development of a robust crystallization procedure.

Authorities withdrew the plant’s GMP certificate, but issued a restricted certificate that allows the facility to continue producing any products considered medically critical to EU members.

RELATED: FDA cites two European companies in separate warning letters

Bristol Laboratories is not the only U.K. producer to find itself crosswise with regulators in the last year. The FDA sent a warning letter to Wallace Cameron, located in Wishaw, Scotland, in October 2016 saying the drugmaker continued to ship products to the U.S. even though it was no longer registered with the agency.

Suggested Articles

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

Private equity player Ampersand Capital Partners is backing another CDMO, this one targeted at sterile injectables.

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.